Ronald Aldridge - PAREXEL International Sr. Director, Investor Relations

  Director
We currently do not have informatin regarding Ronald Aldridge. This executive tanure with PAREXEL International Corp is not currenlty determined.
  Director Since 2016      
781 487-9900  http://www.parexel.com

Management Efficiency

The company has return on total asset (ROA) of 0.05 % which means that it generated profit of $0.05 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.15 % meaning that it created $0.15 on every $100 dollars invested by stockholders.
The company currently holds 671.5 M in liabilities with Debt to Equity (D/E) ratio of 105.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has Current Ratio of 1.42 which is within standard range for the sector.

Similar Executives

Showing few of many executives

DIRECTOR Since

Gregory NordenZoetis
2013
Christine PoonRegeneron Pharmaceuticals
2010
Sanjay KhoslaZoetis
2013
David GreenwayVertex Pharmaceuticals Incorpor
2017
Yingqi XiaOrigin Agritech Limited
2010
Terrence KearneyVertex Pharmaceuticals Incorpor
2011
George SingRegeneron Pharmaceuticals
1988
Bruce CarterDr Reddys Laboratories Ltd
2008
Anthony ColesRegeneron Pharmaceuticals
2017
Charles BakerRegeneron Pharmaceuticals
N/A
Bharat DoshiDr Reddys Laboratories Ltd
2016
Kalpana MorpariaDr Reddys Laboratories Ltd
2007
Yuchun LeeVertex Pharmaceuticals Incorpor
2012
Sangeeta BhatiaVertex Pharmaceuticals Incorpor
2015
Ellen HoffingPerrigo Company Plc
2008
Willie ReedZoetis
2014
Alfred GilmanRegeneron Pharmaceuticals
1990
William SteereZoetis
2013
Shlomo YanaiPerrigo Company Plc
N/A
Larry CordellOrigin Agritech Limited
2012
Marc TessierLavigneRegeneron Pharmaceuticals
2011

Entity Summary

PAREXEL International Corporationration, a biopharmaceutical services company, offer clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology solutions and services for pharmaceutical, biotechnology, and medical device industries worldwide. PAREXEL International Corp (PRXL) is traded on NASDAQ in USA and employs 18,600 people.

PAREXEL International Leadership Team

Michelle Graham, Chief Human Resource Officer, Senior Vice President
Ulf Schneider, Chief Administrative Officer, Senior Vice President
Thomas Senderovitz, Senior Vice President - Clinical Research Services
Dana Callow, Presiding Independent Director
Emma Reeve, Interim CFO, Corporate Vice President Controller
Josef Rickenbach, Founder, Chairman and CEO
Patrick Fortune, Independent Director
Eduard Holdener, Independent Director
Simon Harford, CFO, Senior Vice President
Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access
Gadi Saarony, Senior Vice President - Clinical Research Services
Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center
Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting
Xavier Flinois, President - Perceptive Informatics
Douglas Batt, Sr. VP, General Counsel and Secretary
Sybrand Pretorius, Senior Vice President Chief Scientific Officer
Maykin Ho, Director
Richard Love, Independent Director
Ronald Aldridge, Sr. Director, Investor Relations
Mark Goldberg, President COO
Roland Andersson, Senior Vice President - Clinical Research Services
Christopher Lindop, Independent Director
Ingo Bank, CFO and Sr. VP
David Godwin, Senior Vice President-Global Business

Stock Performance Indicators

Did you try this?

Run Idea Breakdown Now

   

Idea Breakdown

Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
All  Next Launch Module

Currently Active Assets on Macroaxis

PASS   
Purchased over 200 shares of
a day ago
Traded for 14.76
FSLR   
Purchased over 50 shares of
a day ago
Traded for 53.37
AAPL   
Purchased few shares of
a day ago
Traded for 270.71
C   
Purchased over 40 shares of
a day ago
Traded for 75.81
VMW   
Purchased over 20 shares of
a day ago
Traded for 147.08
See also Your Equity Center. Please also try Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Search macroaxis.com